The mitochondrial permeability transition pore as a target of cardioprotective signaling

Abstract

EDITORIAL FOCUSThe mitochondrial permeability transition pore as a target of cardioprotective signalingChristopher P. BainesChristopher P. BainesPublished Online:01 Aug 2007https://doi.org/10.1152/ajpheart.00575.2007This is the final version - click for previous versionMoreSectionsPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat it is has been over two decades since Murry and colleagues (15) published their seminal study describing ischemic preconditioning, a phenomenon whereby brief antecedent periods of ischemia-reperfusion profoundly protect the heart against a subsequent lethal period of ischemia and reperfusion. This intrinsic cardioprotective mechanism has been demonstrated in every animal tested, including human cardiac tissue (20), and, obviously, exploitation of such a powerful protective mechanism would have considerable clinical applications. Consequently, considerable effort has been expended over the past twenty years to try to delineate the mediators and molecular mechanisms that underlie cardioprotection. We now know that various neurohormonal agents and peptides, such as adenosine, bradykinin, and nitric oxide, are released during the preconditioning bursts of ischemia and reperfusion (20). These trigger an increasingly complex series of signal transduction events within the myocyte that somehow confer a “memory” that enables the cell to survive a more pathological period of ischemia. These signal transduction elements primarily consist of kinases, especially protein kinase C (PKC), tyrosine kinases, and mitogen-activated protein kinases (14, 20), with Akt, glycogen synthase kinase 3β, and PKG recently added to the ever-expanding list (6, 14). Nevertheless, despite this extensive knowledge regarding the triggers and signal transduction networks of preconditioning, the critical targets of the protective machinery, the so-called “end effectors,” have remained elusive. However, recent evidence has implicated mitochondria and, in particular, the mitochondrial permeability transition pore, as important targets of cardioprotective signaling.Ischemia-reperfusion induces rapid increases in mitochondrial permeability and volume, a phenomenon known as mitochondrial permeability transition (MPT). These large alterations in membrane permeability lead to a dissipation of the mitochondrial potential (ΔΨm), inhibition of ATP synthesis, swelling, and ultimately mitochondrial rupture (8, 9). The MPT pore, a nonspecific channel that spans both mitochondrial membranes, mediates these increases in mitochondrial permeability (8, 9). The pore itself is permeable to solutes up to 1.5 kDa. This causes equilibration of H+ across the inner membrane, which dissipates ΔΨm. A simultaneous influx of water causes swelling of the mitochondrial matrix, which stretches the mitochondrial membranes to the point where the outer membrane fails. The MPT pore is redox, Ca2+, voltage, and pH sensitive. In particular, increases in matrix Ca2+ and oxidative stress induce MPT pore opening, whereas adenine nucleotides inhibit the pore (8, 9). This is especially germane since ischemia-reperfusion is associated with increases in pore activators (Ca2+ and oxidants) and reductions in pore inhibitors (ATP and ADP). Indeed, studies have shown that MPT occurs at reperfusion, and pharmacological and genetic inhibition of the MPT pore blunts ischemia-reperfusion injury (3, 5, 10, 16).In the context of cardioprotection, several groups have reported that mitochondria isolated from preconditioned hearts are more resistant to Ca2+-induced MPT (2, 11, 12). Moreover, inhibition of key signaling enzymes such as PKC abrogates the inhibitory effect of preconditioning on the MPT pore (6, 13). Similarly, others have shown in cultured myocytes that cardioprotective agents prevent MPT and subsequent cell loss in response to hypoxia-reoxygenation (13, 19). Together, these data strongly indicate that the MPT pore, while not technically an end effector, certainly appears to be an end target of cardioprotection.The excellent study by Townsend and colleagues (18), published in this issue of the American Journal of Physiology-Heart and Circulatory Physiology, offers further proof that inhibition of the MPT pore may ultimately be how cardioprotection actually works. Not content with restricting their studies to one particular model, the authors investigated the effects of a known cardioprotective agent, urocortin, on MPT in isolated mitochondria, both neonatal- and adult-cultured myocytes, as well as ex vivo perfused hearts. Using the “hot dog” technique whereby 2-[3H]deoxyglucose is entrapped in mitochondria that have undergone MPT, the authors showed that a 30-min pretreatment with urocortin significantly reduced the degree of ischemia-reperfusion-induced MPT and concomitant tissue damage in Langendorff-perfused rat hearts. Similarly, mitochondria isolated from the treated, ischemic hearts were less susceptible to Ca2+-induced MPT. In both neonatal and adult rat ventricular myocytes, acute and chronic exposure to urocortin profoundly reduced the loss of ΔΨm, an index of MPT, following simulated ischemia-reperfusion. Thus this state-of-the-art study provides comprehensive evidence that the inhibition of the MPT pore is involved in the cardioprotective effects of urocortin and serves as an excellent example as to how the MPT pore should be studied.How does urocortin, and other cardioprotective agents, cause inhibition of MPT, i.e., how does the protective signal transduction network couple to the MPT pore? Many compounds, including urocortin, induce protection through the activation of the ε-isoform of PKC (14, 20). Recent studies have suggested that PKC-ε may physically translocate to the mitochondria where it could potentially interact with and inhibit the MPT pore (4, 6, 13). However, in the present study, Townsend et al. (18) found very little PKC-ε in a highly purified mitochondrial fraction, with no additional translocation of PKC-ε to the mitochondria following either urocortin or ischemia (18). These data suggest that the coupling of PKC-ε to MPT inhibition may in fact be more indirect. One possibility, as proposed by the authors, is that activation of PKC-ε causes a reduction in the burst of reactive oxygen species upon reperfusion, thus greatly reducing one of the prime activators of the MPT pore. Indeed, using either a redox-sensitive dye or blotting for protein carbonylation, the authors demonstrated that urocortin reduced the increase in oxidative stress at reperfusion, an effect that could be blocked by the PKC inhibitor chelerythrine (18).This of course raises the question of how PKC-ε prevents the production of reactive oxygen species, which at reperfusion are primarily mitochondrial in origin. PKCs have been shown to regulate NAPDH oxidase activity, albeit in a positive manner (17), as well as levels of antioxidants, such as superoxide dismutase (7) and thioredoxin (1). Alternatively, although PKC-ε itself may not localize to mitochondria, other distal kinases, such as Akt and mitogen-activated protein kinases, may do so to inhibit mitochondrial oxidant production or even directly influence the MPT pore. Future studies addressing these suppositions are needed to continue to provide critical insight into the cardioprotective mechanism and, ultimately, into how it can be manipulated in the clinical setting.REFERENCES1 Anema SM, Walker SW, Howie AF, Arthur JR, Nicol F, Beckett GJ. Thioredoxin reductase is the major selenoprotein expressed in human umbilical-vein endothelial cells and is regulated by protein kinase C. Biochem J 342: 111–117, 1999.Crossref | PubMed | ISI | Google Scholar2 Argaud L, Gateau-Roesch O, Chalabreysse L, Gomez L, Loufouat J, Thivolet-Bejui F, Robert D, Ovize M. Preconditioning delays Ca2+-induced mitochondrial permeability transition. Cardiovasc Res 61: 115–122, 2004.Crossref | PubMed | ISI | Google Scholar3 Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658–662, 2005.Crossref | PubMed | ISI | Google Scholar4 Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, Bolli R, Cardwell EM, Ping P. Protein kinase Cε interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92: 873–880, 2003.Crossref | PubMed | ISI | Google Scholar5 Clarke SJ, McStay GP, Halestrap AP. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 277: 34793–34799, 2002.Crossref | PubMed | ISI | Google Scholar6 Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, Critz SD. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97: 329–336, 2005.Crossref | PubMed | ISI | Google Scholar7 Das KC, Guo XL, White CW. Protein kinase Cδ-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. J Biol Chem 273: 34639–34645, 1998.Crossref | PubMed | ISI | Google Scholar8 Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res 70: 191–199, 2006.Crossref | PubMed | ISI | Google Scholar9 Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovasc Res 61: 372–385, 2004.Crossref | PubMed | ISI | Google Scholar10 Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60: 617–625, 2003.Crossref | PubMed | ISI | Google Scholar11 Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534–543, 2002.Crossref | PubMed | ISI | Google Scholar12 Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 549: 513–524, 2003.Crossref | PubMed | ISI | Google Scholar13 Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535–1549, 2004.Crossref | PubMed | ISI | Google Scholar14 Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94: 7–16, 2004.Crossref | PubMed | ISI | Google Scholar15 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136, 1986.Crossref | PubMed | ISI | Google Scholar16 Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652–658, 2005.Crossref | PubMed | ISI | Google Scholar17 Sumimoto H, Miyano K, Takeya R. Molecular composition and regulation of the Nox family NAD(P)H oxidases. Biochem Biophys Res Commun 338: 677–686, 2005.Crossref | PubMed | ISI | Google Scholar18 Townsend PA, Davidson SM, Clarke SJ, Khaliulin I, Carroll CJ, Scarabelli TM, Knight RA, Stephanou A, Latchman DS, Halestrap AP. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly, by reducing oxidative stress. Am J Physiol Heart Circ Physiol May 4, 2007; doi:10.1152/ajpheart.01135.2006.Google Scholar19 Xu M, Wang Y, Hirai K, Ayub A, Ashraf M. Calcium preconditioning inhibits mitochondrial permeability transition and apoptosis. Am J Physiol Heart Circ Physiol 280: H899–H908, 2001.Link | ISI | Google Scholar20 Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83: 1113–1151, 2003.Link | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: C. P. Baines, Div. of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, MLC-7020, 3333 Burnet Ave., Cincinnati, OH 45229 (e-mail: [email protected]) Download PDF Back to Top Next FiguresReferencesRelatedInformationCited ByNon-conventional mitochondrial permeability transition: Its regulation by mitochondrial dynamicsBiochimica et Biophysica Acta (BBA) - Bioenergetics, Vol. 1864, No. 1Cysteine 202 of cyclophilin D is a site of multiple post-translational modifications and plays a role in cardioprotection4 March 2020 | Cardiovascular Research, Vol. 117, No. 1Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s DiseaseJournal of Alzheimer's Disease, Vol. 72, No. 4Pharmacological Targeting of the Mitochondrial Permeability Transition Pore for Cardioprotection22 March 2018Ellagic acid antagonizes Bnip3-mediated mitochondrial injury and necrotic cell death of cardiac myocytesFree Radical Biology and Medicine, Vol. 112The cyclophilin D/Drp1 axis regulates mitochondrial fission contributing to oxidative stress-induced mitochondrial dysfunctions in SH-SY5Y cellsBiochemical and Biophysical Research Communications, Vol. 483, No. 1Involvement of mitochondrial permeability transition pore (mPTP) in cardiac arrhythmias: Evidence from cyclophilin D knockout miceCell Calcium, Vol. 60, No. 6Human Stem Cell-Derived Cardiomyocyte In Vitro Models for Cardiotoxicity Screening18 October 2016Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore22 September 2015 | Cardiovascular Research, Vol. 108, No. 3Modelling the molecular mechanism of protein–protein interactions and their inhibition: CypD–p53 case study14 July 2015 | Molecular Diversity, Vol. 19, No. 4Stress Proteins and the Adaptive Response of the Heart22 September 2014The interplay between cell death signaling pathways in the heartTrends in Cardiovascular Medicine, Vol. 24, No. 8The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent20 March 2014 | Cardiovascular Research, Vol. 103, No. 1Protein S-nitrosylation in preconditioning and postconditioning25 March 2014 | Experimental Biology and Medicine, Vol. 239, No. 6Reactive Oxygen Species (ROS) and Cardiac Ischemia and Reperfusion Injury3 May 2014Mouse Models of Heart FailureRedox balance and cardioprotection25 October 2013 | Basic Research in Cardiology, Vol. 108, No. 6Cyclophilin D Deficiency Rescues Axonal Mitochondrial Transport in Alzheimer’s Neurons31 January 2013 | PLoS ONE, Vol. 8, No. 1Mitochondrial Dysfunction—A Pharmacological Target in Alzheimer's Disease3 May 2012 | Molecular Neurobiology, Vol. 46, No. 1Cysteine 203 of Cyclophilin D Is Critical for Cyclophilin D Activation of the Mitochondrial Permeability Transition PoreJournal of Biological Chemistry, Vol. 286, No. 46Mitochondrial Unselective Channels throughout the eukaryotic domainMitochondrion, Vol. 11, No. 3Cardioprotective Pathways During Reperfusion: Focus on Redox Signaling and Other Modalities of Cell SignalingAntioxidants & Redox Signaling, Vol. 14, No. 5Low-intensity aerobic interval training attenuates pathological left ventricular remodeling and mitochondrial dysfunction in aortic-banded miniature swineCraig A. Emter, and Christopher P. Baines1 November 2010 | American Journal of Physiology-Heart and Circulatory Physiology, Vol. 299, No. 5Therapeutic hypothermia cardioprotection via Akt- and nitric oxide-mediated attenuation of mitochondrial oxidantsZuo-Hui Shao*, Willard W. Sharp*, Kimberly R. Wojcik, Chang-Qing Li, Mei Han, Wei-Tien Chang, Srinivasan Ramachandran, Jing Li, Kimm J. Hamann, and Terry L. Vanden Hoek1 June 2010 | American Journal of Physiology-Heart and Circulatory Physiology, Vol. 298, No. 6Cell signaling and cancer-possible targets for therapyJournal of Cellular Physiology, Vol. 283The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) familyBiochemical Pharmacology, Vol. 77, No. 2Role of wild-type estrogen receptor-β in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cellsJ. M. Flynn, S. D. Dimitrijevich, M. Younes, G. Skliris, L. C. Murphy, and P. R. Cammarata1 September 2008 | American Journal of Physiology-Endocrinology and Metabolism, Vol. 295, No. 3 More from this issue > Volume 293Issue 2August 2007Pages H903-H904 Copyright & PermissionsCopyright © 2007 by the American Physiological Societyhttps://doi.org/10.1152/ajpheart.00575.2007PubMed17513492History Published online 1 August 2007 Published in print 1 August 2007 Metrics